Basal Cell Carcinoma

P1, N=56, Recruiting, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Recruiting

This review consolidates existing evidence and suggests that mixed cancer syndromes, especially LFS, LS, and HBOC but also pathogenic ATM and CHEK2 variants may predispose individuals to skin cancers, warranting tailored screening and preventive measures. On the basis of emerging evidence, we recommend dermatologic evaluation and individualized UV protection strategies for patients with reviewed hereditary cancer syndromes to reduce skin cancer risk and enhance early detection.

In addition, TRPS1 exhibited higher AUC values than GATA3 and adipophilin in differentiating primary and recurrent SCs, although the difference was not significant. Collectively, our findings indicate that the TRPS1/GATA3/adipophilin-based model demonstrated excellent discriminatory efficacy for eyelid malignancies (Kappa = 0.784, micro-average F1 = 0.882, AUC-ROC = 0.964 [95%CI:0.934-0.994]), achieving clinical-grade performance.

Our findings suggest that CA-IX is strongly expressed in periocular BCC tissues and may also serve as a systemic marker, given its elevated serum levels. The lower levels of antioxidant enzymes may be an indicator of possible systemic oxidative stress in BCC patients.

Immunosuppression with calcineurin inhibitor (CNI) plus azathioprine (AZA) was independently associated with increased skin cancer risk (odds ratio [OR] 9.41, p = 0.044), especially for SCC (OR 6.6, p = 0.027)...Skin cancer is a relevant long-term complication after HTx, particularly SCC in patients receiving AZA. Our findings support limiting AZA use and reinforce the importance of structured dermatologic surveillance and early mammalian target of rapamycin conversion strategies to improve long-term outcomes.

P=N/A, N=42, Active, not recruiting, Institut de Cancérologie de Lorraine | Recruiting --> Active, not recruiting | Trial completion date: May 2025 --> Mar 2026

Nevertheless, preclinical studies have proposed very promising results, and to date, there have been no human clinical trials. Further research is needed to assess the safety, pharmacokinetics, and therapeutic potential of curcumin-based interventions in dermatologic oncology.

These are (i) inappropriate activation of the hedgehog signaling pathway (HHSP) due to formation of key driver mutations; (ii) interference with the presentation of tumor-specific antigens/neoantigens to cytotoxic T-cells; (iii) attenuation of the influx of anti-tumor natural killer cells; (iv) the recruitment and activation of immune suppressive regulatory T-cells; and (v) localized and systemic immune dysfunction achieved via elevated levels of soluble co-inhibitory immune checkpoint proteins (ICPs). The final section is focused on current and emerging pharmacologic and immune-based therapies.

P1/2, N=18, Recruiting, Instituto Oncológico Dr Rosell

PARPi-FL, a fluorescent derivative of Olaparib, enables rapid, specific, and high-contrast imaging of BCC in preclinical and ex vivo human studies. Optimized application protocols confirm its safety and translational promise for noninvasive diagnosis and image-guided surgery.

The suggested clinical diagnosis for Gorlin syndrome type 1 was confirmed by genetic analysis. Loss-of-function mutations in PTCH1 gene, including large deletions, are known to promote the formation of neoplasms and craniomaxillofacial phenotype observed in BCNS1 by relieving the inhibition of the sonic hedgehog pathway, which is implicated in cell proliferation.

P=N/A, N=54, Not yet recruiting, Case Comprehensive Cancer Center